Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial

Matthew D. Hale; Matthew Nankivell; Gordon G. Hutchins; Sally P. Stenning; Ruth E. Langley; Wolfram Mueller; Nicholas P. West; Alexander I. Wright; Darren Treanor; Lindsay C. Hewitt; William H. Allum; David Cunningham; Jeremy D. Hayden; Heike I. Grabsch

doi:10.18632/oncotarget.12723

Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial

Matthew D. Hale, Matthew Nankivell, Gordon G. Hutchins, Sally P. Stenning, Ruth E. Langley, Wolfram Mueller, Nicholas P. West, Alexander I. Wright, Darren Treanor, Lindsay C. Hewitt, William H. Allum, David Cunningham, Jeremy D. Hayden, Heike I. Grabsch

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	77565-77575
Number of pages	11
Journal	Oncotarget
Volume	7
Issue number	47
DOIs	https://doi.org/10.18632/oncotarget.12723
Publication status	Published - 22 Nov 2016

Keywords

biomarker
neoadjuvant chemotherapy
oesophageal cancer
proportion of tumour
tumour stroma

Access to Document

10.18632/oncotarget.12723

Cite this

Hale, M. D., Nankivell, M., Hutchins, G. G., Stenning, S. P., Langley, R. E., Mueller, W., West, N. P., Wright, A. I., Treanor, D., Hewitt, L. C., Allum, W. H., Cunningham, D., Hayden, J. D., & Grabsch, H. I. (2016). Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial. Oncotarget, 7(47), 77565-77575. https://doi.org/10.18632/oncotarget.12723

Hale, Matthew D. ; Nankivell, Matthew ; Hutchins, Gordon G. ; Stenning, Sally P. ; Langley, Ruth E. ; Mueller, Wolfram ; West, Nicholas P. ; Wright, Alexander I. ; Treanor, Darren ; Hewitt, Lindsay C. ; Allum, William H. ; Cunningham, David ; Hayden, Jeremy D. ; Grabsch, Heike I. / Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial. In: Oncotarget. 2016 ; Vol. 7, No. 47. pp. 77565-77575.

@article{1e070139f72049f5ba590ef6209c02a5,

title = "Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial",

keywords = "biomarker, neoadjuvant chemotherapy, oesophageal cancer, proportion of tumour, tumour stroma",

author = "Hale, {Matthew D.} and Matthew Nankivell and Hutchins, {Gordon G.} and Stenning, {Sally P.} and Langley, {Ruth E.} and Wolfram Mueller and West, {Nicholas P.} and Wright, {Alexander I.} and Darren Treanor and Hewitt, {Lindsay C.} and Allum, {William H.} and David Cunningham and Hayden, {Jeremy D.} and Grabsch, {Heike I.}",

year = "2016",

month = nov,

day = "22",

doi = "10.18632/oncotarget.12723",

language = "English",

volume = "7",

pages = "77565--77575",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "47",

}

Hale, MD, Nankivell, M, Hutchins, GG, Stenning, SP, Langley, RE, Mueller, W, West, NP, Wright, AI, Treanor, D, Hewitt, LC, Allum, WH, Cunningham, D, Hayden, JD & Grabsch, HI 2016, 'Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial', Oncotarget, vol. 7, no. 47, pp. 77565-77575. https://doi.org/10.18632/oncotarget.12723

Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial. / Hale, Matthew D.; Nankivell, Matthew; Hutchins, Gordon G.; Stenning, Sally P.; Langley, Ruth E.; Mueller, Wolfram; West, Nicholas P.; Wright, Alexander I.; Treanor, Darren; Hewitt, Lindsay C.; Allum, William H.; Cunningham, David; Hayden, Jeremy D.; Grabsch, Heike I.

In: Oncotarget, Vol. 7, No. 47, 22.11.2016, p. 77565-77575.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial

AU - Hale, Matthew D.

AU - Nankivell, Matthew

AU - Hutchins, Gordon G.

AU - Stenning, Sally P.

AU - Langley, Ruth E.

AU - Mueller, Wolfram

AU - West, Nicholas P.

AU - Wright, Alexander I.

AU - Treanor, Darren

AU - Hewitt, Lindsay C.

AU - Allum, William H.

AU - Cunningham, David

AU - Hayden, Jeremy D.

AU - Grabsch, Heike I.

PY - 2016/11/22

Y1 - 2016/11/22

KW - biomarker

KW - neoadjuvant chemotherapy

KW - oesophageal cancer

KW - proportion of tumour

KW - tumour stroma

U2 - 10.18632/oncotarget.12723

DO - 10.18632/oncotarget.12723

M3 - Article

VL - 7

SP - 77565

EP - 77575

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 47

ER -